Zusammenfassung
Das Prostatakarzinom ist heute in Deutschland das häufigste Organmalignom des
Mannes. Die Bestimmung des Prostata-spezifischen Antigens (PSA) spielt in der
frühen Diagnose wie auch im Therapiemonitoring dieser potentiell heilbaren Erkrankung
eine unverzichtbare Rolle. Dargestellt sind hier die Möglichkeiten aber auch die
Grenzen der Verwendung des PSA in der Diagnostik des Prostatakarzinoms insbesondere
in der Abgrenzung von der benignen Prostatahyperplasie.
Summary
Prostate cancer has become the most frequently diagnosed organ malignancy of men
in Germany. The use of the prostate-specific antigen (PSA) for the early diagnosis
and treatment monitoring of this potentially curable disease has become indispensable.
This article describes the possibilities of PSA-based diagnosis and treatment
of prostate cancer and also its limitations in discriminating from benign prostatic
hyperplasia.
Schlüsselwörter
Prostatakarzinom - Prostata-spezifisches Antigen - Vorsorge - Früherkennung
Keywords
prostate cancer - prostate-specific antigen - screening - diagnosis
Literatur
- 01 Aus G, Abbou C C, Heidenreich A, Schmid H P, Poppel van H, Wolff M MJ, Zattoni F.
Guidelines on prostate cancer. Arnheim; European Association of Urology; 2003
- 02
Catalona W J, Smith D S, Ratliff T L, Dodds K M, Coplen D E, Yuan J J, Petros J A,
Andriole G L.
Measurement of prostate-specific antigen in serum as a screening test for prostate
cancer.
N Engl J Med.
1991;
324
156-1161
- 03
Catalona W J, Richie J P, Ahmann F R, Hudson M A, Scardino P T, Flanigan R C, deKernion J B,
Ratlif T L, Kavoussi L R, Dalkin B L, Waters M B, MacFarlane M T, Southwick P C.
Comparison of digital rectal examination and serum prostate specific antigen
(PSA) in the early detection of prostate cancer: results of a multicentre clinical
trial of 6630 men.
J Urol.
1994;
151
1283-1290
- 04
Cooner E H, Mosley B R, Rutherford C I.
Prostate cancer detection in a clinical urological practice by ultrasonography,
digital rectal examination and prostate specific antigen.
J Urol.
1990;
143
1146-1154
- 05
Ellis W J, Brawer N K.
PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.
Urol Clin N Am.
1993;
20
621-625
- 06
Froschermaier S E, Pilarsky C P, Wirth M P.
Clinical significance of the determination of non-complexed prostate-specific
antigen as a marker for prostate carcinoma.
Urology.
1996;
47
(4)
525-528
- 07
Hakenberg O W, Wirth M P, Hermann T, Alken P, Kovacs G, Muller R P, Ahlemann L, Schalkhäuser
K.
Recommendations for the treatment of localized prostate cancer by permanent
interstitial brachytherapy.
Urol Int.
2003;
70
15-20
- 08
Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.
Prostate cancer screening in the Tyrol, Austria: experience and results.
Eur J Cancer.
2000;
36
1322-1355
- 09
Kleer E, Larson-Keller J J, Zincke H, Oesterling J E.
Ability of preoperative serum prostate-specific antigen value to predict pathologic
stage and DNA ploidy: Influence of clinical stage and tumour grade.
Urology.
1993;
41
207-216
- 10 Krebsregister, A.b., Krebs in Deutschland. Häufigkeit und Trends. Vol. 4.
überarbeitete Auflage 2004
- 11
Li T S, Beling C G.
Isolation and characterization of two specific antigens of humanl seminal plasma.
Fertil Steril.
1973;
24
134-137
- 12
Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl C G, Hugossson J.
Characteristics of screening detected prostate cancer in men 50 to 66 years
old with 3-5 ng/ml prostate-specific antigen.
J Urol.
1998;
159
899-903
- 13
Oesterling J E, Martin S K, Bergstrahl E J, Lowe F C.
The use of prostate-specific antigen in staging patients with newly diagnosed
prostate cancer.
JAMA.
1993;
269
57-60
- 14
Partin A W, Pound C R, Clemens J Q. et al .
Serum PSA after anatomic radical prostatectomy.
Urol Clin North Am.
1993;
20
713-725
- 15
Partin A W, Kattan M V, Subong E N P, Walsh P C, Wojno K J, Oesterling J E, Scardino P T,
Pearson J D.
Combination of prostate-specific antigen, clinical stage and Gleason Score to
predict pathological stage of localized prostate cancer.
JAMA.
1997;
277
1445-1451
- 16
Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L.
Discordance of assay methods creates pitfalls for the interpretation of prostate-specific
antigen values.
Prostate.
1996;
7(Suppl)
3-16
- 17
Stamey
A, Freiha F S, McNeal J E, Redwine E A, Whittemore A S, Schmid H P.
Localized prostate cancer. Relationship of tumour volume to clinical significance
for treatment of prostate cancer.
Cancer.
1993;
71
(S 3)
933-938
- 18
Wang M C, Valenzuela L A, Murphy G P. et al .
Purification of human prostate specific antigen.
Invest Urol.
1979;
17
159-163
Korrespondenzadresse
PD Dr. med. habil. Oliver W. Hakenberg
Klinik und Poliklinik für Urologie
Universitätsklinikum „Carl Gustav Carus”
der Technischen Universität Dresden
Fetscherstraße 74
01307 Dresden
eMail: Oliver.Hakenberg@uniklinikum-dresden.de
